---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000036"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-06-25T20:02:15+00:00"
generated_at: "2026-06-25T20:03:16.917572+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Keros appoints Anne Prener to Board of Directors, effective July 1, 2026

## Summary
- Anne Prener, M.D., Ph.D., appointed as Class III director with term expiring at 2029 annual meeting.
- Initial equity grants: $150K option and $150K RSU, each vesting quarterly over three years.
- Annual compensation: $75K option, $75K RSU, and $41,500 cash retainer for board service.
- Dr. Prener brings clinical development leadership; formerly CEO of Imbria, Freeline, Gyroscope, and exec at Baxalta and Novo Nordisk.

## SEC filing metadata
- accession: 0001664710-26-000036
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-06-25T20:02:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000036/0001664710-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000036/kros-20260623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000036
- JSON: https://secwatch.observer/filing/0001664710-26-000036.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.